Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-25

Am I missing something here?

To me, in laymans tems, PAR have realised that this stuff not only works, it works for extended duration.
Hence the introduction of the additional follow-up period to measure the duration of effect.

Hence:

• An additional follow-up period to 12-months has also been accepted by the ethicscommittee to assist Paradigm gather additional data on the medium-long termcombined structure-modifying and symptom-modifying effects of PPS on Knee OA(KOA).

• The additional follow-up period to 12 months and the disease modifying synovialfluid biomarkers are important to the Company to support maximum reimbursementprice for Zilosul® once registered. $$$

Clearly results to date a promising and deliving positive results.
When you go to market you need to know how long this will last for and it will have a considerable impact to valuation.

I think this is positive news.
I also think it will not impact the FDA response due back within days.

Yes, it's a slighly slower burn now, but wow, strap in...